No. |
KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * [Number of genes] |
KEGG DRUG * |
DrugBank |
Disease ID * [Number of diseases] |
1 | Adipocytokine signaling pathway 1 gene, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
2 | African trypanosomiasis 2 genes, 3 drugs (DrugBank), 10 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
3 | AGE-RAGE signaling pathway in diabetic complications 3 genes, 4 drugs (DrugBank), 19 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[1] JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
4 | Allograft rejection 3 genes, 2 drugs (DrugBank), 24 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
5 | Alzheimer disease 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
6 | Amoebiasis 4 genes, 4 drugs (DrugBank), 21 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[2] IL1R1, IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
7 | Antifolate resistance 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
8 | Antigen processing and presentation 1 gene, 1 drug (DrugBank), 1 disease shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
9 | Autoimmune thyroid disease 2 genes, 1 drug (DrugBank), 24 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
10 | C-type lectin receptor signaling pathway 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
11 | Cell adhesion molecules (CAMs) 2 genes, 1 drug (DrugBank), 24 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
12 | Cellular senescence 1 gene, 1 drug (DrugBank), 4 diseases shown |
[1] IL1A |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
13 | Chagas disease (American trypanosomiasis) 2 genes, 3 drugs (DrugBank), 10 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
14 | Chemokine signaling pathway 2 genes, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK2, JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
15 | Cholinergic synapse 1 gene, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
16 | Complement and coagulation cascades 1 gene, 1 drug (DrugBank), 11 diseases shown |
[1] SERPINC1 |
D07510 |
Heparin |
[11] 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 |
17 | Cytokine-cytokine receptor interaction 6 genes, 6 drugs (DrugBank), 28 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] IL1R1, IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
18 | Cytosolic DNA-sensing pathway 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
19 | EGFR tyrosine kinase inhibitor resistance 3 genes, 4 drugs (DrugBank), 23 diseases shown |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
20 | Epstein-Barr virus infection 3 genes, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
21 | Fluid shear stress and atherosclerosis 5 genes, 4 drugs (DrugBank), 21 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] IL1R1, IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
22 | Graft-versus-host disease 5 genes, 4 drugs (DrugBank), 30 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
23 | Growth hormone synthesis, secretion and action 1 gene, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
24 | Hematopoietic cell lineage 5 genes, 5 drugs (DrugBank), 28 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] IL1R1, IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
25 | Hepatitis B 4 genes, 2 drugs (DrugBank), 13 diseases shown |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[4] JAK1, JAK2, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
26 | Hepatitis C 3 genes, 3 drugs (DrugBank), 13 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK1, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
27 | Herpes simplex virus 1 infection 5 genes, 5 drugs (DrugBank), 19 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
28 | HIF-1 signaling pathway 2 genes, 3 drugs (DrugBank), 17 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
29 | Human cytomegalovirus infection 4 genes, 7 drugs (DrugBank), 33 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
30 | Human papillomavirus infection 2 genes, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK1, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
31 | Human T-cell leukemia virus 1 infection 4 genes, 3 drugs (DrugBank), 24 diseases shown |
[2] IL1R1, IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK1, JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
32 | IL-17 signaling pathway 2 genes, 3 drugs (DrugBank), 10 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
33 | Inflammatory bowel disease (IBD) 3 genes, 3 drugs (DrugBank), 10 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
34 | Inflammatory mediator regulation of TRP channels 2 genes, 3 drugs (DrugBank), 21 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
35 | Influenza A 6 genes, 5 drugs (DrugBank), 19 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
36 | Intestinal immune network for IgA production 2 genes, 1 drug (DrugBank), 24 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
37 | JAK-STAT signaling pathway 6 genes, 5 drugs (DrugBank), 23 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[4] JAK1, JAK2, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
38 | Kaposi sarcoma-associated herpesvirus infection 4 genes, 3 drugs (DrugBank), 26 diseases shown |
[1] CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
39 | Legionellosis 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
40 | Leishmaniasis 5 genes, 5 drugs (DrugBank), 19 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
41 | Malaria 2 genes, 3 drugs (DrugBank), 10 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
42 | MAPK signaling pathway 3 genes, 3 drugs (DrugBank), 21 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
43 | Measles 5 genes, 4 drugs (DrugBank), 19 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
44 | Natural killer cell mediated cytotoxicity 1 gene, 1 drug (DrugBank), 1 disease shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
45 | Necroptosis 7 genes, 5 drugs (DrugBank), 19 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[4] JAK1, JAK2, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
46 | NF-kappa B signaling pathway 2 genes, 3 drugs (DrugBank), 21 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
47 | NOD-like receptor signaling pathway 3 genes, 4 drugs (DrugBank), 19 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK1, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
48 | Non-alcoholic fatty liver disease (NAFLD) 3 genes, 4 drugs (DrugBank), 22 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
49 | Non-small cell lung cancer 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
50 | Osteoclast differentiation 6 genes, 6 drugs (DrugBank), 27 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK1, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
51 | Pancreatic cancer 1 gene, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
52 | Pathogenic Escherichia coli infection 2 genes, 3 drugs (DrugBank), 21 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
53 | Pathways in cancer 5 genes, 5 drugs (DrugBank), 23 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
54 | PD-L1 expression and PD-1 checkpoint pathway in cancer 3 genes, 3 drugs (DrugBank), 13 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
55 | Pertussis 2 genes, 2 drugs (DrugBank), 10 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
56 | PI3K-Akt signaling pathway 4 genes, 4 drugs (DrugBank), 23 diseases shown |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
57 | Primary immunodeficiency 1 gene, 1 drug (DrugBank), 9 diseases shown |
[1] JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
58 | Prion diseases 2 genes, 2 drugs (DrugBank), 10 diseases shown |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
59 | Prolactin signaling pathway 1 gene, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
60 | Prostate cancer 1 gene, 1 drug (DrugBank), 17 diseases shown |
[1] IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
61 | Proteasome 1 gene, 1 drug (DrugBank), 1 disease shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
62 | Rheumatoid arthritis 5 genes, 4 drugs (DrugBank), 30 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
63 | Salmonella infection 3 genes, 3 drugs (DrugBank), 10 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
64 | Shigellosis 2 genes, 3 drugs (DrugBank), 21 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
65 | Signaling pathways regulating pluripotency of stem cells 3 genes, 2 drugs (DrugBank), 13 diseases shown |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
66 | Systemic lupus erythematosus 3 genes, 2 drugs (DrugBank), 24 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
67 | T cell receptor signaling pathway 1 gene, 1 drug (DrugBank), 1 disease shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
68 | TGF-beta signaling pathway 1 gene, 1 drug (DrugBank), 1 disease shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
69 | Th1 and Th2 cell differentiation 5 genes, 3 drugs (DrugBank), 13 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[4] JAK1, JAK2, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
70 | Th17 cell differentiation 8 genes, 8 drugs (DrugBank), 33 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1R1 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[4] JAK1, JAK2, JAK3, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
71 | TNF signaling pathway 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
72 | Toll-like receptor signaling pathway 3 genes, 3 drugs (DrugBank), 30 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
73 | Toxoplasmosis 4 genes, 3 drugs (DrugBank), 13 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[3] JAK1, JAK2, TYK2 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
74 | Transcriptional misregulation in cancer 2 genes, 2 drugs (DrugBank), 32 diseases shown |
[1] CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IL1R2 |
D02934 |
Anakinra |
[17] 2, 13, 15, 19, 37, 41, 46, 49, 50, 56, 65, 84, 86, 106, 107, 266, 299 |
75 | Tuberculosis 5 genes, 5 drugs (DrugBank), 19 diseases shown |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
[2] JAK1, JAK2 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
76 | Type I diabetes mellitus 5 genes, 4 drugs (DrugBank), 30 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
[1] IFNG |
D11120 |
Emapalumab |
[1] 107 |
[2] IL1A, IL1B |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
77 | Viral carcinogenesis 2 genes, 2 drugs (DrugBank), 13 diseases shown |
[1] JAK1 |
D10308 |
Baricitinib |
[8] 41, 46, 49, 50, 93, 107, 265, 325 |
[2] JAK1, JAK3 |
D09970 |
Tofacitinib |
[9] 46, 49, 50, 51, 84, 96, 97, 107, 271 |
78 | Viral myocarditis 2 genes, 1 drug (DrugBank), 24 diseases shown |
[2] CD80, CD86 |
D03203 |
Abatacept |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
79 | Viral protein interaction with cytokine and cytokine receptor 1 gene, 2 drugs (DrugBank), 17 diseases shown |
[1] IL6R |
D10161 |
Sarilumab |
[5] 41, 46, 84, 107, 271 |
D02596 |
Tocilizumab |
[16] 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
80 | Yersinia infection 1 gene, 2 drugs (DrugBank), 10 diseases shown |
[1] IL1B |
D09315 |
Canakinumab |
[9] 46, 56, 84, 106, 107, 108, 113, 266, 269 |
D06635 |
Rilonacept |
[4] 51, 106, 107, 266 |